RANI - Rani Therapeutics Holdings, Inc. Stock Price, Fair Value and News

$2.05-0.01 (-0.49%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RANI Price Action

Last 7 days

-17%

Last 30 days

-20.2%

Last 90 days

-33.2%

Trailing 12 Months

1.5%

RANI RSI Chart

RANI Valuation

Market Cap

59.1M

Price/Earnings (Trailing)

-1.59

Price/Sales (Trailing)

28.46

EV/EBITDA

-1.24

Price/Free Cashflow

-1.49

RANI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RANI Fundamentals

RANI Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

-50.66%

Rev. Growth (Qtr)

-5.69%

RANI Earnings

Earnings (TTM)

-37.2M

Earnings Growth (Yr)

-38.33%

Earnings Growth (Qtr)

-86.95%

RANI Profitability

EBT Margin

-3268.32%

Return on Equity

-643.71%

Return on Assets

-85.38%

Free Cashflow Yield

-67.06%

RANI Investor Care

Shares Dilution (1Y)

12.85%

Diluted EPS (TTM)

-2.48

RANI Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.0M	2.5M	2.1M	0
2023	2.1M	3.0M	3.4M	3.3M
2022	2.3M	2.0M	1.6M	1.2M
2021	1.0M	1.6M	2.2M	2.7M
2020	0	0	0	462.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

CEO	Mr. Talat Imran
WEBSITE	ranitherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	163

Rani Therapeutics Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Rani Therapeutics Holdings, Inc.? What does RANI stand for in stocks?

RANI is the stock ticker symbol of Rani Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rani Therapeutics Holdings, Inc. (RANI)?

As of Wed Nov 20 2024, market cap of Rani Therapeutics Holdings, Inc. is 59.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RANI stock?

You can check RANI's fair value in chart for subscribers.

Is Rani Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether RANI is over valued or under valued. Whether Rani Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Rani Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RANI.

What is Rani Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RANI's PE ratio (Price to Earnings) is -1.59 and Price to Sales (PS) ratio is 28.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RANI PE ratio will change depending on the future growth rate expectations of investors.